NCT05407519 2023-03-22A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionAnhui Provincial HospitalPhase 2 Recruiting40 enrolled